Advertisement
| epidermal growth factor receptor therapy side effects: Dermatologic Principles and Practice in Oncology Mario E. Lacouture, 2013-11-26 The first book focusing specifically on frequent and frequently disabling side effects involving the skin, hair and nails in cancer patients According to the World Health Organization, there are approximately thirty million people living with a diagnosis of cancer – the majority of whom will receive surgery, systemic therapy, and/or radiation, and who will suffer from dermatologic adverse events. Dermatologists and oncologists are only beginning to grapple with these events, which pose serious quality-of-life issues with so many patients, and will become more prevalent as survival rates improve, thanks in part to new cancer treatments and drug regimens. Concentrating on a topic that has only been briefly touched upon by other texts, this book offers a focused perspective on the clinical presentation, underlying pathophysiologic mechanisms, and management of skin, hair, and nail conditions for oncologists, dermatologists, and allied practitioners. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients: • Covers in detail the dermatologic adverse events of oncologic therapies, clinical presentations, and treatment recommendations • Enables dermatologists and other practitioners to significantly improve the care of patients with cancer • Addresses the dermatologic adverse events of cancer therapies used globally, of which a large number are found in developing countries • Emphasizes prophylactic measures – based on treatments used and type of cancer – to prevent the appearance of adverse events • Provides built-in discussions on patient education for practical counseling during therapies • Offers rapid-reference sections on topical dermatology drugs The first book to present dermatologic conditions in cancer patients and survivors in a uniform and in-depth manner, Dermatologic Principles and Practice in Oncology is ideal for oncologists, oncology nurses, and dermatologists who wish to take better care of those with adverse skin, hair, and nail conditions. |
| epidermal growth factor receptor therapy side effects: Inpatient Dermatology Misha Rosenbach, Karolyn A. Wanat, Robert G. Micheletti, Laura A. Taylor, 2018-11-03 Inpatient Dermatology is a concise and portable resource that synthesizes the most essential material to help physicians with recognition, differential diagnosis, work-up, and treatment of dermatologic issues in the hospitalized patient. Complete with hundreds of clinical and pathologic images, this volume is both an inpatient dermatology atlas and a practical guide to day-one, initial work-up, and management plan for common and rare skin diseases that occur in the inpatient setting. Each chapter is a bulleted, easy-to-read reference that focuses on one specific inpatient dermatologic condition, with carefully curated clinical photographs and corresponding histopathologic images to aid readers in developing clinical-pathologic correlation for the dermatologic diseases encountered in the hospital. Before each subsection the editors share diagnostic pearls, explaining their approach to these challenging conditions. This book is structured to be useful to physicians, residents, and medical students. It spans dermatology, emergency medicine, internal medicine, infectious disease, and rheumatology. Inpatient Dermatology is the go-to guide for hospital-based skin diseases, making even the most complex inpatient dermatologic issues approachable and understandable for any clinician. |
| epidermal growth factor receptor therapy side effects: Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy , 2018-11-21 Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. - Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research - Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms - Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment |
| epidermal growth factor receptor therapy side effects: Pancreatic Cancer Douglas B. Evans, Peter W.T. Pisters, James L. Abruzzese, 2002 The MD Anderson Solid Tumor Oncology series presents cutting-edge surgical treatment and medical therapy for specific sites. This volume, Pancreatic Cancer, addresses epidemiology and molecular biology, inherited syndromes, staging, surgical techniques, multimodality therapy, and emerging therapies. The individual chapters focus on narrow, specific topics to produce a reference work of value to those interested in pancreatic cancer from a clinical and translational research perspective. A must-have for surgical oncologists and general surgeons. |
| epidermal growth factor receptor therapy side effects: Adverse Reactions to Biologics L. Puig, W. Gulliver, 2017-11-07 In many areas of medicine physicians still face the great challenge of finding therapies that will meet the patients’ needs. In dermatology the challenge has arisen on multiple fronts through advances in the understanding of the immunopathogenesis of many inflammatory and malignant cutaneous disorders. Breakthroughs, combined with significant developments in targeted immunotherapy, have resulted in improved outcomes as these newer therapies are being used for both approved indications and as off-label therapies for various chronic inflammatory skin disorders and many forms of skin cancer. In the expectation that by truly understanding the safety profile of these targeted therapies patients’ outcomes will be significantly improved, this book offers insights into topics such as adverse reactions, infectious complications and the perioperative use of biologics in psoriasis, immunogenicity of biologic therapies, paradoxical reactions, safety of biologics used to treat autoimmune bullous diseases and primary cutaneous lymphomas, adverse reactions and skin manifestations of therapies targeting melanoma and non-melanoma skin cancer and other neoplastic diseases. Eminent researchers with extensive clinical experience have contributed to this publication, providing an in-depth overview of the latest knowledge in this field. |
| epidermal growth factor receptor therapy side effects: Safety of Biologics Therapy Brian A. Baldo, 2016-08-12 This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences. |
| epidermal growth factor receptor therapy side effects: Hepatocellular Carcinoma Yujin Hoshida, 2019-08-05 This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC. |
| epidermal growth factor receptor therapy side effects: Metronomic Chemotherapy Guido Bocci, Giulio Francia, 2014-09-04 This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic. |
| epidermal growth factor receptor therapy side effects: Precision Medicine in Oncology Bulent Aydogan, James A. Radosevich, 2020-11-02 A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others. |
| epidermal growth factor receptor therapy side effects: Free Energy Calculations Christophe Chipot, Andrew Pohorille, 2007-01-08 Free energy constitutes the most important thermodynamic quantity to understand how chemical species recognize each other, associate or react. Examples of problems in which knowledge of the underlying free energy behaviour is required, include conformational equilibria and molecular association, partitioning between immiscible liquids, receptor-drug interaction, protein-protein and protein-DNA association, and protein stability. This volume sets out to present a coherent and comprehensive account of the concepts that underlie different approaches devised for the determination of free energies. The reader will gain the necessary insight into the theoretical and computational foundations of the subject and will be presented with relevant applications from molecular-level modelling and simulations of chemical and biological systems. Both formally accurate and approximate methods are covered using both classical and quantum mechanical descriptions. A central theme of the book is that the wide variety of free energy calculation techniques available today can be understood as different implementations of a few basic principles. The book is aimed at a broad readership of graduate students and researchers having a background in chemistry, physics, engineering and physical biology. |
| epidermal growth factor receptor therapy side effects: Theranostic Approach for Pancreatic Cancer Ganji Purnachandra Nagaraju, Sarfraz Ahmad, 2020-01-15 Theranostic Approach for Pancreatic Cancer modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property through introducing new strategies and drugs for tackling the disease. It brings information about ongoing research as well as clinical data about pancreatic cancer and provides detailed descriptions about diagnostic and therapeutic options for easy understanding. This book discusses several topics related to pancreatic cancer such as stem cells, drug resistance and pancreatic tumor microenvironment, the latest developments in chemotherapy for metastatic cancer and chemoprevention, and epigenome as a therapeutic strategy. Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, oncologists, and several members of the biomedical field who need to understand more about the diagnosis and treatment of pancreatic cancer. Provides information on the roadblocks of chemotherapy in patients with newly diagnosed and metastatic pancreatic cancer Discusses treatment options available currently as well as prospective options for the future Focuses especially on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways as already tested types of treatment |
| epidermal growth factor receptor therapy side effects: Oral Precancer Peter Thomson, 2012-04-23 Without early detection, oral cancer is deadly. Protect your patients by applying the latest clinical interventions. Rates of new oral cancer cases continue to increase and mortality rates remain alarmingly high. Oral cancer may be preceded by clinically identifiable precancerous changes in the oral mucosa, which offer a therapeutic window of opportunity to intervene and halt disease progression to carcinoma development. Written and edited by prominent researchers in the field, Oral Precancer: Reviews current scientific research on precancer conditions of the oral cavity providing evidence-based analysis of the nature and behavior of potentially malignant and deforming oral diseases Explains the principles of prevention, diagnosis and management of potentially malignant disorders of the oral cavity Details a practical and reliable interventional treatment strategy to facilitate early diagnosis and effective treatment of both precancer and early invasive carcinoma Contains a chapter devoted to illustrative case histories, high-quality, color, clinical photos, reference sections in each chapter listing relevant review articles, and more From start to finish, Oral Precancer offers undergraduate students, clinicians, and professors an invaluable resource to minimise the morbidity and mortality of this most significant and life threatening of oral conditions. |
| epidermal growth factor receptor therapy side effects: Novel Therapies in Head and Neck Cancer: Beyond the Horizon Maie A. St. John, No hee Park, 2020-06-29 Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume Twelve, provides a high-level synthesis of the latest treatments and outcomes relating to head and neck cancer. Chemotherapy and immunotherapy for those cancer types are rapidly evolving, and an updated source based on the expertise of internationally renowned researchers is necessary. This book discusses the outcome of recent trials using chemotherapy, novel approaches for HPV+ SCCA, cases in which immunotherapy is more likely to be successful, and precision medicine based on target therapies. Additionally, new approaches for rare diseases in head and neck and novel drug delivery platforms are presented. This book will be a very useful source so that students, scientists and clinicians who can be facile with the data, build on what is known, and continue to offer cutting-edge, validated therapies to all patients. |
| epidermal growth factor receptor therapy side effects: Physiologic and Pathologic Angiogenesis Dan Simionescu, Agneta Simionescu, 2017-04-05 The purpose of this book is to highlight novel advances in the field and to incentivize scientists from a variety of fields to pursue angiogenesis as a research avenue. Blood vessel formation and maturation to capillaries, arteries, or veins is a fascinating area which can appeal to multiple scientists, students, and professors alike. Angiogenesis is relevant to medicine, engineering, pharmacology, and pathology and to the many patients suffering from blood vessel diseases and cancer, among others. We are hoping that this book will become a source of inspiration and novel ideas for all. |
| epidermal growth factor receptor therapy side effects: Infectious Complications in Cancer Patients Valentina Stosor, Teresa R. Zembower, 2014-04-05 While advances in both the treatment of cancer and the management of its complications have led to significant improvement in patient survival, infections remain a significant cause of morbidity and mortality in patients with neo plastic disease. In this patient population, infection risk results from a complex interplay between the host’s underlying immunodeficiencies, local tumor effects and treatment-induced immunosuppression. New chemotherapeutic approaches and antimicrobial prophylaxis and treatment practices continue to shape the spectrum of infections in these patients. Clinicians who treat infections in cancer patients are continually challenged by the emergence of new pathogens and by the increasing antimicrobial resistance of established ones. The aim of this book is to emphasize unique aspects of management of infectious diseases in the cancer patient. With the increasing complexity of this patient population, optimal management requires a multidisciplinary approach and this fact is fully reflected in the contributions, all from recognized authorities in the field. Ultimately, it is hoped that this volume will assist specialists in infectious diseases and haematology/oncology in the diagnosis, management and prevention of infection and optimization of the overall care of patients with malignancies. |
| epidermal growth factor receptor therapy side effects: Hepatotoxicity Hyman J. Zimmerman, 1999 Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury. |
| epidermal growth factor receptor therapy side effects: Perioperative Chemotherapy U. Metzger, F. Largiader, H.-J. Senn, 2012-12-06 One reason for failure to cure solid tumors by surgery appears to be the impossibility of controlling metastases that are present but latent at the time of operation. This failure is a common clinical experience with aggressive neoplasms. but it is not always appreciated in tumors with longer survival times. e. g .• breast and colon cancer. In addition. recent evidence indicates that after resection of a primary tumor micrometas tases from it might be enhanced by suppression of immune and reticu loendothelial functions of the host. Other factors, such as increase of coagulability and stress in the perioperative period, can also promote tumor growth. The development of new metastases might be facilitated by cells forced into the circulation during operative manipulations. Such events could be important for the outcome of treatment and it is suggested that preventive measures should be directed to this systemic component of solid tumors. Radical surgery can reduce the number of tumor cells to a subclinical 3 6 stage (10 to 10 cells) in which chemotherapy might be more effective than in advanced stages. Chemotherapy, on the other hand, might aggravate the surgical morbidity by influencing the wound healing pro cess, by decreasing the immune response, and/or by toxicity to the bone marrow and to the gastrointestinal tract, for example. |
| epidermal growth factor receptor therapy side effects: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy , 2018-03-28 Targeting Cell Survival Pathways to Enhance Response to Chemotherapy encompasses recently developed molecular targeting agents and approaches that suppress cell survival signaling. Cell survival signaling attenuates the effectiveness of conventional chemotherapy and numerous mechanisms have been described, and continue to be described, which contribute to cell survival in the face of chemotherapy treatment. Key pathways leading to chemoresistance emanate from growth factor receptors, PI3K, STAT3, anti-apoptotic Bcl-2 family members, autophagy, and the DNA damage response pathway. New advances have underscored the potential of targeting each of these cell survival mechanisms to improve responsiveness to chemotherapy. This book reviews these recent advances and provides a foundational background and hints of new opportunities for basic, translational, and clinical investigators focused on improving therapeutic responses to chemotherapy. - Presents cutting-edge agents and approaches with proved success in different model systems that can be translated to a different type of cancer - Brings updated information to be used to propose new clinical trials investigating innovative strategies for improving responses to chemotherapy - Provides mechanistic details to help guide the design of laboratory studies associated with clinical trials |
| epidermal growth factor receptor therapy side effects: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| epidermal growth factor receptor therapy side effects: Successes and Limitations of Targeted Cancer Therapy S. Peters, R.A. Stahel, 2014-02-19 The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies. |
| epidermal growth factor receptor therapy side effects: HER2-Positive Breast Cancer Sara Hurvitz, Kelly McCann, 2018-07-26 Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies. |
| epidermal growth factor receptor therapy side effects: CDC Yellow Book 2018: Health Information for International Travel Centers for Disease Control and Prevention CDC, 2017-04-17 THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad. |
| epidermal growth factor receptor therapy side effects: Tumors of the Central Nervous System - Primary and Secondary , 2014 |
| epidermal growth factor receptor therapy side effects: Pulmonary Adenocarcinoma: Approaches to Treatment Leora Horn, 2018-10-24 Get a quick, expert overview of the latest treatment and management approaches for adenocarcinoma of the lung, including novel therapeutics in immunotherapy and targeted therapies. This practical title, edited by Dr. Leora Horn, offers succinct coverage of clinically-focused topics and guidelines, making it an ideal resource for practicing and trainee oncologists and other members of the cancer care team. - Discusses surgical approaches, molecular testing, adjuvant therapy, first- and second-line therapy, and much more. - Helps you translate current research and literature into practical information for daily practice. - Consolidates today's available information on this timely topic into one convenient resource. |
| epidermal growth factor receptor therapy side effects: Cancer and the Heart Michael S. Ewer, 2013 The book begins with the basic science behind the medical applications of the knowledge: cardiovascular biology, pathways, and their relationship to cancer treatment and principles of chemotherapy and immunotherapy. The second section consists of an overview and classification of anti-cancer drugs and a look at their cardiotoxicity. The third section looks at cardiac imaging in the cancer patient, including cardiac ultrasound, Doppler imaging, nuclear imaging, magnetic resonance imaging, and computed tomography in the cancer patient. In section four, management of cardiac disease in the cancer patient is discussed, including cardiac rhythm disturbances and heart failure. Cardiac emergencies and interventions are described as is preoperative assessment of the cancer patient for non- cardiovascular surgery. The final section includes a range of topics such as the pericardium, cardiovascular effects of endocrine treatments, primary cardiac tumors and malignancies of the myocardium and pericardium. Cardiac monitoring during clinical trials and pulmonary concerns are also addressed, as are psychosocial, social, economic, and legal issues of the cancer patient with heart disease. |
| epidermal growth factor receptor therapy side effects: Histological Typing of Lung and Pleural Tumours W.D. Travis, T.V. Colby, B. Corrin, Y. Shimosato, E. Brambilla, 2012-12-06 with contributions by Pathologists from 14 Countries |
| epidermal growth factor receptor therapy side effects: Kinase Drug Discovery Richard A. Ward, Frederick Goldberg, 2012 Kinase drug discovery remains an area of significant interest across academia and in the pharmaceutical industry. There are now around 13 FDA approved small molecule drugs which target kinases and many more compounds in various stages of clinical development. Although there have been a number of reviews/publications on kinase research, this book fills a gap in the literature by considering the current and future opportunities and challenges in targeting this important family of enzymes. The book is forward-looking and identifies a number of hot topics and key areas for kinase drug discovery over the coming years. It includes contributions from highly respected authors with a combined experience in the industry of well over 200 years, which has resulted in a book of great interest to the kinase field and across drug discovery more generally. Readers will gain a real insight into the huge challenges and opportunities which this target class has presented drug discovery scientists. The many chapters cover a wide breadth of topics, are well written and include high quality colour and black and white images. Topics covered include an outline of how medicinal chemistry has been able to specifically exploit this unique target class, along with reflections on the mechanisms of kinases inhibitors. Also covered is resistance to kinase inhibitors caused by amino acid mutations, case studies of kinase programs and reviews areas beyond protein kinases and beyond the human kinome. Also described are modern approaches to finding kinase leads and the book finishes with a reflection of how kinase drug discovery may progress over the coming years. |
| epidermal growth factor receptor therapy side effects: SANFORD GUIDE TO ANTIMICROBIAL THERAPY. , 2020 |
| epidermal growth factor receptor therapy side effects: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| epidermal growth factor receptor therapy side effects: Cancer in Sub-Saharan Africa Olufunso Adebola Adedeji, 2018-06-12 This book discusses the current state of cancer pathway as it is relevant to sub-Saharan Africa and highlights differences in epidemiology and the underlying problems with management. It outlines the current practice and opinions in all forms of cancer, also highlighting future prospects. Starting by providing background information on the epidemiology and genomic variations, the book then goes on to look at Infection-related cancers and continues to prostate GI, breast cancer and ovarian and cervical cancer. The last part of the book focuses on delivery of affordable and accessible care. Palliative services and primary and transnational research, as well as clinical trials are also discussed. Written by a team of authors based in the UK, Nigeria, South Africa and the US. this book offers an overview of the current state and challenges of cancer care in sub-Saharan Africa, and it would be valuable to policy makers, researchers, funding organisations, and can be an adjunct to standard text books for students, residents and established doctors. |
| epidermal growth factor receptor therapy side effects: Antibody Fusion Proteins Steven M. Chamow, Avi Ashkenazi, 1999-04-13 Thoroughly detailed and illustrated, this book examines the construction, properties, applications, and problems associated with specific types of fusion molecules used in clinical and research medicine. The editors present an overview of the field, followed by nine chapters divided into two general sections based on the two primary parts of the antibody molecule: Fab fusion proteins and Fc fusion proteins. In addition, numerous renowned scientists in the field have contributed outlines demonstrating man-made molecules that will be required not only to overcome the limitations of monoclonal antibodies, but also to extend the principle of selective targeting. Divided into specific, accessible sections, Antibody Fusion Proteins includes: * Chapters describing Fc fusion proteins, as well as several classes of antigen-binding proteins * Complete details on the design and molecular construction of genetically engineered fusion molecules * Useful information on molecular purification, large-scale production, practical applications, and their therapeutic potential * The latest data on forming fusion proteins with toxins, cytokines, or enzymes that can activate a prodrug |
| epidermal growth factor receptor therapy side effects: Baran and Dawber's Diseases of the Nails and their Management Robert Baran, R. P. R. Dawber, David A. R. de Berker, Ekhart Haneke, Antonella Tosti, 2001-12-04 This new edition brings together five leading authorities in nail surgery in this well established and definitive textbook. The entire text is extended in this edition, and particular emphasis is placed on the advances in treatments that have taken place in recent years. Considerable strides have been made in the treatment of fungal diseases (onychomycoses) with the appearance of new therapeutic agents. There is also much greater coverage of nail surgery to reflect the increasing involvement of the dermatologist in this field. The section on nail tumours has also been expanded. Drs Baran and Dawber have been joined by David de Berker, Eckhart Haneke and Antonella Tosti on the editorial team. This move is representative of the major European contribution to the field of nail surgery in recent years. Significant contribution has come from Dr Elvin Zook, the eminent American hand surgeon, who has helped to ensure that the book is as relevant in North America as it is in Europe. |
| epidermal growth factor receptor therapy side effects: Hepatobiliary Cancer Paul H. Sugarbaker, 2014-09-01 |
| epidermal growth factor receptor therapy side effects: Side Effects of Medical Cancer Therapy Mario A. Dicato, Eric Van Cutsem, 2018-06-27 This is the second edition of a well-received book that reflects the state of the art in cancer medical therapies and their side-effects, including immunotherapy and chemotherapeutic drugs. All chapters have been fully updated to include all the latest progress in drug discovery such as targeted therapies for each cancer type. From issues such as preservation of fertility to antiemetic therapy the book provides a very comprehensive overview of the field. The book includes a new chapter on immuno-oncology drugs. Organised by organ system, it lists the toxicity, side-effects and measures of prevention pertaining to each type of drug used in cancer therapy. The most dangerous side-effects are priority so as to alert the reader to their importance. Designed for quick reference in the clinical setting this book is primarily aimed at established medical oncologists but will also appeal to junior doctors, trainees, pharmacists and nurses. |
| epidermal growth factor receptor therapy side effects: Cancer Nursing Connie Yarbro, Debra Wujcik, Barbara Holmes Gobel, 2011 A new and revised version of this best-selling reference! For over eighteen years, best-selling Cancer Nursing: Principles and Practice has provided oncology nurses with the latest information on new trends in the rapidly changing science of oncology. Now, in its Seventh Edition, Cancer Nursing has been completely revised and updated to reflect key new developments. New topics covered include targeted therapy, hypersensitivity reactions, mucositis, and family and caregiver issues. With 27 new chapters featuring insights from key authors, the Seventh Edition is a must-have resource for every oncology nurse. |
| epidermal growth factor receptor therapy side effects: Dermatologic Reactions to Cancer Therapies Gabriella Fabbrocini, Mario E. Lacouture, Antonella Tosti, 2019-03-21 Chemotherapy and radiotherapy for cancer can have devastating side effects on the skin of a patient. This innovative guide for both dermatologists and oncologists gives a good introduction both to therapy regimes and to dermatological management for medical professionals treating their patients. |
| epidermal growth factor receptor therapy side effects: Skin Tumors and Reactions to Cancer Therapy in Children Jennifer T. Huang, Carrie C. Coughlin, 2017-11-25 In today’s era of genomic testing, targeted cancer therapies, and increased cancer survivorship, recognition and management of oncologic disease in children is becoming more important to address. This book familiarizes clinicians with the range of oncologic issues that pediatric dermatologists encounter, including the diagnosis and management of various skin tumors, cutaneous reactions to cancer therapies, and both acute and long term complications of cancer therapy. Written and edited by experts in the field, Pediatric Skin Tumors and Cutaneous Reactions to Cancer Therapy explores these important topics, beginning with the discussion of various skin tumors, and associated genetic syndromes, followed by chapters on acute cutaneous reactions to traditional and targeted cancer therapies, graft versus host disease, and opportunistic skin infections. This book concludes with the discussion of both malignant and nonmalignant late effects of the skin in childhood cancer survivors. |
| epidermal growth factor receptor therapy side effects: Pathobiology of Cancer Regimen-Related Toxicities Stephen T. Sonis, Dorothy M. Keefe, 2013-01-28 The contents of this book will be organized into three sections. The first section defines the scope, impact and behaviour of cancer regimen-related toxicities and frames the issue of balancing treatment success and physiological cost. In the second segment of the book, the most current thinking around the pathobiology of specific, common, and representative toxicities is presented by leading researchers and translational scientists. The final portion of the book discusses the common biological relationships between toxicities, bioinformatical approaches to analysing key and common pathways, and strategies for the development of effective interventions. |
| epidermal growth factor receptor therapy side effects: Andrew's Diseases of the Skin E-Book William D. James, Dirk Elston, Timothy Berger, 2011-03-21 The 11th Edition of the classic Andrews’ Diseases of the Skin, by Drs. William D. James, Timothy G. Berger and Dirk M. Elston, provides the ultimate foundation in dermatology with comprehensive guidance to effectively diagnose and treat a wide range of skin conditions. These highly respected authors balance evidence-based treatment guidelines with advice from their own clinical experience, offering a practical and realistic medical perspective. Updated throughout with the latest dermatologic findings and a new chapter on cosmetic surgical techniques, this title helps you keep current, improve your skills, and prepare for exams. It is an indispensable, convenient reference for trainees and practicing dermatologists. Practice with confidence through the valued authorship of seasoned professionals Dr. William D. James, Dr. Timothy G. Berger, and Dr. Dirk M. Elston. Rapidly improve your knowledge of skin conditions through a concise, clinically focused, user-friendly format. Obtain thorough guidance on clinical presentation and therapy for a full range of common and rare skin diseases. Confirm your diagnoses by comparing your clinical findings to more than 1,150 illustrations, 40% of which are brand new. Update your surgical skills with chapters devoted to basic dermatologic, laser, and cosmetic surgery, contributed by Dr. Issac M. Neuhaus. |
| epidermal growth factor receptor therapy side effects: EGFR Inhibitors—Advances in Research and Application: 2013 Edition , 2013-06-21 EGFR Inhibitors—Advances in Research and Application: 2013 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Lapatinib in a concise format. The editors have built EGFR Inhibitors—Advances in Research and Application: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Lapatinib in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of EGFR Inhibitors—Advances in Research and Application: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
ONS Guidelines™ for Cancer Treatment–Related Skin Toxicity
Common skin toxicities that will be covered by these guidelines include epidermal growth factor receptor inhibitor (EGFRI) rash, hand-foot skin reaction, hand-foot syndrome or palmar-plantar …
Anticipating and managing the cutaneous side effects of …
Aims: Epidermal growth factor receptor inhibitor (EGFRi) therapy for tumor suppression produces significant cutaneous toxicity that may necessitate dose reduction or treatment cessation. This …
Clinical signs, pathophysiology and management of skin …
This review outlines the broad spectrum of cutaneous side-effects of EGFR inhibitors, discusses possible underlying mechanisms and provides practical guide-lines for the management based …
Dermatologic side effects associated with the epidermal …
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Cetuximab, erlotinib, and gefitinib have been approved for patients …
Cutaneous adverse effects of combination epidermal growth …
Epidermal growth factor receptor inhibitors (EGFRIs) and immune checkpoint inhibitors (ICIs) show promising eficacy in colorectal cancer and head and neck squamous cell carcinoma …
Cutaneous adverse effects of biologic medications
cause cutaneous adverse effects. The authors discuss the cutaneous adverse effects of tumor necrosis factor (TNF) alpha inhibitors, epidermal growth factor receptor (EGFR) inhibitors, …
The Most Common Cutaneous Side Effects of Epidermal …
life. Early management of cutaneous side effects of EGFRI may prevent severe, extensive symptoms, the need for dose reduction, or antitumor therapy interruption. This indicates a …
NCCN Task Force Report: Management of Dermatologic and …
Postin-flammatory side effects, such as telangiectasias, ery-thema, and hyperpigmentation, tend to occur 5 to 9 weeks after initiation of EGFR inhibitor therapy.34 This section discusses …
Dermatological Side-Effects Developing in Patients Using
Papulopustular eruption was observed in 63% (12/19) of patients using epidermal growth factor receptor inhibitors. The most common finding in the nails was brittleness-tenderness. Dry …
Mechanisms of cutaneous toxicities to EGFR inhibitors - Nature
Abstract | The increased target specificity of epidermal growth factor receptor (EGFR) inhibitors (EGFRIs) is associated with the reduction or abolition of nonspecific and haematopoietic side...
Cutaneous Side Effects of Epidermal Growth Factor Receptor …
growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) is cutaneous adverse events of epidermal growth factor receptor (EGFR) inhibitors. Numerous studies show …
Cutaneous side effects of epidermal growth factor receptor …
Dec 12, 2006 · However, their growing use has been accompanied by an increasing incidence of cutaneous toxicities, which can cause serious discomfort and be disabling. This review …
Epidermal Growth Factor and Epidermal Growth Factor …
healing. Currently, there is no standard therapy to alleviate the side effects caused by EGFRi administration except to reduce or eliminate EGFRi us-age. Therefore, side effects from these …
Cutaneous Side-Effects of Epidermal Growth Factor Receptor …
with unique and dramatic dermatologic side effects. We report 2 patients with NSCLC developing a typical acneiform (papulo-pustular) eruption shortly after initiation of EGFR-TKI. KEY …
EGFR Inhibitors and Cutaneous Complications: A Practical
Epidermal growth factor receptor inhibitors (EGFRIs) are increasingly being used for malig-nancies of epithelial origin. Though these therapies are better tolerated than conventional …
Prevention and Treatment of Acneiform Rash in Patients …
The most commonly reported side effect is acneiform (papulopustular) rash; Table 1 lists the incidence rate for each EFGR inhibitor. Acneiform rash is typically localized to the face, scalp, …
Skin Toxicity - ONS
Skin toxicities addressed in this guideline include epidermal growth factor receptor inhibitor (EGFRI) rash, hand-foot skin reaction, hand-foot syndrome (or palmar-plantar erythroderma), …
Erlotinib-induced trichomegaly of eyelashes in lung cancer …
Clinicians often encounter a spectrum of cutaneous side efects associated with of EGFR-TKIs, including ac-neiform rash, pruritus, and less commonly, xerosis, paronychia, skin fissures, and …
Nail toxicity associated with epidermal growth factor receptor ...
Dec 12, 2006 · Although a follicular eruption is the most frequent cutaneous manifestation of epidermal growth factor receptor inhibition, ingrown nails, paronychia, and xerosis and …
review Annals of Oncology
Aug 13, 2010 · cetuximab and panitumumab, or epidermal growth factor receptor (EGFR) small molecule tyrosine kinase inhibitors, such as erlotinib and gefitinib, have expanded the …
ONS Guidelines™ for Cancer Treatment–Related Skin Toxicity
Common skin toxicities that will be covered by these guidelines include epidermal growth factor receptor inhibitor (EGFRI) rash, hand-foot skin reaction, hand-foot syndrome or palmar-plantar …
Anticipating and managing the cutaneous side effects of …
Aims: Epidermal growth factor receptor inhibitor (EGFRi) therapy for tumor suppression produces significant cutaneous toxicity that may necessitate dose reduction or treatment cessation. This …
Clinical signs, pathophysiology and management of skin …
This review outlines the broad spectrum of cutaneous side-effects of EGFR inhibitors, discusses possible underlying mechanisms and provides practical guide-lines for the management based …
Dermatologic side effects associated with the epidermal …
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Cetuximab, erlotinib, and gefitinib have been approved for patients …
Cutaneous adverse effects of combination epidermal …
Epidermal growth factor receptor inhibitors (EGFRIs) and immune checkpoint inhibitors (ICIs) show promising eficacy in colorectal cancer and head and neck squamous cell carcinoma …
Cutaneous adverse effects of biologic medications
cause cutaneous adverse effects. The authors discuss the cutaneous adverse effects of tumor necrosis factor (TNF) alpha inhibitors, epidermal growth factor receptor (EGFR) inhibitors, …
The Most Common Cutaneous Side Effects of Epidermal …
life. Early management of cutaneous side effects of EGFRI may prevent severe, extensive symptoms, the need for dose reduction, or antitumor therapy interruption. This indicates a …
NCCN Task Force Report: Management of Dermatologic and …
Postin-flammatory side effects, such as telangiectasias, ery-thema, and hyperpigmentation, tend to occur 5 to 9 weeks after initiation of EGFR inhibitor therapy.34 This section discusses …
Dermatological Side-Effects Developing in Patients Using
Papulopustular eruption was observed in 63% (12/19) of patients using epidermal growth factor receptor inhibitors. The most common finding in the nails was brittleness-tenderness. Dry …
Mechanisms of cutaneous toxicities to EGFR inhibitors - Nature
Abstract | The increased target specificity of epidermal growth factor receptor (EGFR) inhibitors (EGFRIs) is associated with the reduction or abolition of nonspecific and haematopoietic side...
Cutaneous Side Effects of Epidermal Growth Factor …
growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) is cutaneous adverse events of epidermal growth factor receptor (EGFR) inhibitors. Numerous studies show …
Cutaneous side effects of epidermal growth factor …
Dec 12, 2006 · However, their growing use has been accompanied by an increasing incidence of cutaneous toxicities, which can cause serious discomfort and be disabling. This review …
Epidermal Growth Factor and Epidermal Growth Factor …
healing. Currently, there is no standard therapy to alleviate the side effects caused by EGFRi administration except to reduce or eliminate EGFRi us-age. Therefore, side effects from these …
Cutaneous Side-Effects of Epidermal Growth Factor …
with unique and dramatic dermatologic side effects. We report 2 patients with NSCLC developing a typical acneiform (papulo-pustular) eruption shortly after initiation of EGFR-TKI. KEY …
EGFR Inhibitors and Cutaneous Complications: A Practical …
Epidermal growth factor receptor inhibitors (EGFRIs) are increasingly being used for malig-nancies of epithelial origin. Though these therapies are better tolerated than conventional …
Prevention and Treatment of Acneiform Rash in Patients …
The most commonly reported side effect is acneiform (papulopustular) rash; Table 1 lists the incidence rate for each EFGR inhibitor. Acneiform rash is typically localized to the face, scalp, …
Skin Toxicity - ONS
Skin toxicities addressed in this guideline include epidermal growth factor receptor inhibitor (EGFRI) rash, hand-foot skin reaction, hand-foot syndrome (or palmar-plantar erythroderma), …
Erlotinib-induced trichomegaly of eyelashes in lung cancer …
Clinicians often encounter a spectrum of cutaneous side efects associated with of EGFR-TKIs, including ac-neiform rash, pruritus, and less commonly, xerosis, paronychia, skin fissures, and …
Nail toxicity associated with epidermal growth factor …
Dec 12, 2006 · Although a follicular eruption is the most frequent cutaneous manifestation of epidermal growth factor receptor inhibition, ingrown nails, paronychia, and xerosis and …
review Annals of Oncology
Aug 13, 2010 · cetuximab and panitumumab, or epidermal growth factor receptor (EGFR) small molecule tyrosine kinase inhibitors, such as erlotinib and gefitinib, have expanded the …
